New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia
A Fullmer, H Kantarjian, J Cortes… - Leukemia & lymphoma, 2011 - Taylor & Francis
Although imatinib revolutionized the management of chronic myeloid leukemia (CML),
recent data indicate a transformation in the treatment approach likely in the near future. The …
recent data indicate a transformation in the treatment approach likely in the near future. The …
Overcoming resistance in chronic myelogenous leukemia
S Cooper, FJ Giles, MR Savona - Leukemia & lymphoma, 2009 - Taylor & Francis
Chronic myeloid leukemia is defined by the acquired genetic mutation, t (9; 22), which leads
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …
The next generation of therapies for chronic myeloid leukemia
A Quintás-Cardama, JE Cortés - Clinical Lymphoma and Myeloma, 2009 - Elsevier
Therapy with the tyrosine kinase inhibitor (TKI) represents the current standard first-line
therapy for the management of patients with chronic myeloid leukemia (CML). Although most …
therapy for the management of patients with chronic myeloid leukemia (CML). Although most …
[图书][B] Suppression of BCR-ABL by siRNA-loaded nanoparticles for the treatment of Chronic Myeloid Leukemia
KE Gavrilov - 2015 - search.proquest.com
Abstract Chronic Myeloid Leukemia (CML) is caused by the fusion oncoprotein BCR-ABL,
whose dysregulated tyrosine kinase activity drives malignant transformation. In this thesis, I …
whose dysregulated tyrosine kinase activity drives malignant transformation. In this thesis, I …
Chronic myelogenous leukemia (CML)
N von Bubnoff, L Pleyer, D Neureiter, V Faber… - … Myeloid Neoplasias and …, 2010 - Springer
Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder with an
uncontrolled production of maturing neutrophils being the predominant laboratory feature …
uncontrolled production of maturing neutrophils being the predominant laboratory feature …
Therapy of Advanced‐Stage and Resistant Chronic Myeloid Leukemia
Summary In the developed world, 85–90% of patients with chronic myeloid leukemia are
diagnosed in the chronic phase. With introduction of imatinib (IM), the treatment of chronic …
diagnosed in the chronic phase. With introduction of imatinib (IM), the treatment of chronic …
イマチニブ耐性CML に対する新規チロシンキナーゼ阻害剤の開発
木村晋也 - 臨床血液, 2009 - jstage.jst.go.jp
進行した. そして 2 年目の 1 年間では, この年次増悪率は 7.5% と増加し, イマチニブ単剤では早晩
再発をきたし治癒は望めないとする悲観的な予測もされた. しかし, 3 年目以降の年次憎悪率は年々 …
再発をきたし治癒は望めないとする悲観的な予測もされた. しかし, 3 年目以降の年次憎悪率は年々 …